Cabinet papers:
Allowing sales of cold medicines containing pseudoephedrine
Misuse of Drugs (Pseudoephedrine) Amendment Bill 2024: Approval for Introduction
Cabinet material, associated briefing and regulatory impact statement: Improving the Medicinal Cannabis Scheme to better support economic and research opportunities.
Proactive release of the Cabinet material relating to the transitioning of labelling requirements for medicines newly scheduled as controlled drugs under the Misuse of Drugs Act 1975.
These documents provide context around the Government's decision to amend the Therapeutic Products Bill to create an exemption regime for small-scale natural health product producers and remove most obligations for rongoā.
Cabinet material relating to:
Misuse of Drugs (Classification and Presumption of Supply) Commencement Order 2022 and the Misuse of Drugs (Classification and Presumption of Supply) Amendment Order 2022
Misuse of Drugs Amendment Regulations 2022 and Medicines Amendment Regulations (No 2) 2022.
Cabinet material related to the increase to the Combined Pharmaceutical Budget in the 2023/24 financial year.
Cabinet has agreed to repeal the Medicines Act 1981 (Medicines Act) and Dietary Supplements Regulations 1985 (made under the Food Act 2014) and replace them with new legislation that will regulate medicines, medical devices, active pharmaceutical ingredients, and natural health products (therapeutic products).
HEALTH SERVICES AND SYSTEMS
EQUITY
Exploring the impacts of the health system on minorities within the population, notably including Māori, Pacifica, Asians and LGBTQI.
DRUGS, DEVICE AND DIAGNOSTICS
PUBLIC HEALTH
DIGITAL HEALTH
TE TIRITI